251 related articles for article (PubMed ID: 32157369)
1. Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data.
Robles-Perez A; Dorca J; Castellví I; Nolla JM; Molina-Molina M; Narváez J
Rheumatol Int; 2020 May; 40(5):719-726. PubMed ID: 32157369
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
4. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
[TBL] [Abstract][Full Text] [Related]
5. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
6. Effects of rituximab in connective tissue disorders related interstitial lung disease.
Lepri G; Avouac J; Airò P; Anguita Santos F; Bellando-Randone S; Blagojevic J; Garcia Hernàndez F; Gonzalez Nieto JA; Guiducci S; Jordan S; Limaye V; Maurer B; Selva-O'Callaghan A; Riccieri V; Distler O; Matucci-Cerinic M; Allanore Y
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):181-185. PubMed ID: 27749242
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Rituximab in Connective Tissue Disease related Interstitial Lung Disease.
Fitzgerald DB; Moloney F; Twomey M; O'Connell JO; Cronin O; Harty L; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):215-21. PubMed ID: 26422566
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease.
Sharp C; McCabe M; Dodds N; Edey A; Mayers L; Adamali H; Millar AB; Gunawardena H
Rheumatology (Oxford); 2016 Jul; 55(7):1318-24. PubMed ID: 27060110
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
Doyle TJ; Dhillon N; Madan R; Cabral F; Fletcher EA; Koontz DC; Aggarwal R; Osorio JC; Rosas IO; Oddis CV; Dellaripa PF
J Rheumatol; 2018 Jun; 45(6):841-850. PubMed ID: 29606668
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
Fischer A; Brown KK; Du Bois RM; Frankel SK; Cosgrove GP; Fernandez-Perez ER; Huie TJ; Krishnamoorthy M; Meehan RT; Olson AL; Solomon JJ; Swigris JJ
J Rheumatol; 2013 May; 40(5):640-6. PubMed ID: 23457378
[TBL] [Abstract][Full Text] [Related]
11. Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study.
Chan C; Ryerson CJ; Dunne JV; Wilcox PG
BMC Pulm Med; 2019 Oct; 19(1):192. PubMed ID: 31672127
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia.
Tanaka M; Koike R; Sakai R; Saito K; Hirata S; Nagasawa H; Kameda H; Hara M; Kawaguchi Y; Tohma S; Takasaki Y; Dohi M; Nishioka Y; Yasuda S; Miyazaki Y; Kaneko Y; Nanki T; Watanabe K; Yamazaki H; Miyasaka N; Harigai M
Mod Rheumatol; 2015 Jul; 25(4):609-14. PubMed ID: 25496409
[TBL] [Abstract][Full Text] [Related]
13. Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease.
Kim K; Lee J; Jo YS
Ther Adv Respir Dis; 2023; 17():17534666231212301. PubMed ID: 37991015
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.
Oldham JM; Lee C; Valenzi E; Witt LJ; Adegunsoye A; Hsu S; Chen L; Montner S; Chung JH; Noth I; Vij R; Strek ME
Respir Med; 2016 Dec; 121():117-122. PubMed ID: 27888985
[TBL] [Abstract][Full Text] [Related]
15. Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.
Zhao Y; Gao Y; Petnak T; Cheungpasitporn W; Thongprayoon C; Zhang X; Moua T
Respir Res; 2022 Jun; 23(1):164. PubMed ID: 35729565
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Wang Y; Li L
Int J Rheum Dis; 2023 Feb; 26(2):225-235. PubMed ID: 36378118
[TBL] [Abstract][Full Text] [Related]
17. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus.
Yamano Y; Taniguchi H; Kondoh Y; Ando M; Kataoka K; Furukawa T; Johkoh T; Fukuoka J; Sakamoto K; Hasegawa Y
Respirology; 2018 Nov; 23(11):1041-1048. PubMed ID: 30011421
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Xing NS; Fan GZ; Yan F; Liu YP; Zhang R
Int Immunopharmacol; 2021 Jun; 95():107524. PubMed ID: 33721757
[TBL] [Abstract][Full Text] [Related]
19. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
20. Imaging of Pulmonary Manifestations of Connective Tissue Diseases.
Ahuja J; Arora D; Kanne JP; Henry TS; Godwin JD
Radiol Clin North Am; 2016 Nov; 54(6):1015-1031. PubMed ID: 27719973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
